Anticipating a regional shift:Preparing the pharmaceutical industry for real-world evidence requirements across East Asia analogous to a Conditional Reimbursement List frameworkOA
Across global health systems,policymakers continue to face the persistent tension between the urgency of providing early access to innovative therapies and the enduring uncertainties surrounding pre-launch clinical evidence.This tension has grown more pronounced as high-cost specialty medicines,cellular therapies,and precision oncology treatments increasingly dominate expenditure growth.In response,many regulatory and reimbursement bodies worldwide have shifted toward conditional access models supported by post-launch evidence requirements.
Hong Li;Dimitrios Tsourougiannis;David Bin-Chia Wu;Chee-Jen Chang
Department of Pharmacy Practice and Administrative Sciences,James L.Winkle College of Pharmacy,University of Cincinnati,Cincinnati,OH,45267,USAShionogi Pharmaceuticals,Osaka,530-0011,JapanSaw Swee Hock School of Public Health,National University of Singapore,Singapore,117549,Singapore School of Pharmacy,Faculty of Health&Medical Sciences,Taylor’s University,Subang Jaya,47500,MalaysiaDepartment of Biomedical Sciences,College of Medicine,Chang Gung University,Taoyuan,33302,Taiwan,China Graduate Institute of Health Data Science,College of Intelligent Computing,Chang Gung University,Taoyuan,33302,Taiwan,China Research Service Center for Health Information,Chang Gung University,Taoyuan,33302,Taiwan,China
医药卫生
East Asiaregional shiftprecision oncology treatmentscellular therapiespharmaceutical industryreal world evidenceconditional reimbursementhigh cost specialty medicines
《Pharmacoeconomics and Policy》 2026 (2)
P.55-59,5
评论